Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BioNaze is a consumer health brand focused on oral probiotic lozenges intended to support ear, nose, throat, sinus, and oral health. Its flagship product is a commercially available probiotic supplement containing the patented strains BLIS K12 and BL-04. The brand markets its products for upper-respiratory and oral microbiome support, including bad breath, post-nasal drip, sinus issues, and related ENT complaints. BioNaze appears to operate as a health supplement business rather than a drug-development biotech company, with commercial sales through its own websites and major e-commerce channels. Publicly available information indicates a small private company/brand with a direct-to-consumer model and no disclosed clinical-stage therapeutic pipeline.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on BioNaze.